Guillain-Barré syndorme and COVID-19: a post-infection complication of important acknowledgement
DOI:
https://doi.org/10.52428/20756208.v17i43.265Keywords:
Guillain-Barré syndrome, SARS-CoV-2 infection, COVID-19Abstract
Guillain-Barré syndrome is an autoimmune disease with flaccid paralysis as its characteristic syndrome. It is associated to infections caused by agents such as Campilobacter jejuni. Posterior to the SARS-CoV-2 break out, it was associated as a sequel in more than 13 countries. It’s now being exposed the case of a patient with Guillain-Barré who presented COVID-19 approximately 21 days before his hospital admission, he arrived with deambulation incapacity, preserved sensibility, and abolished osteotendinous reflexes. The diagnosis was confirmed by an electromyography study, being compatible with the AMAN variant.
Downloads
References
Guillain-Barré syndrome [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2022 [citado 28Abril2022]. Disponible en: https://www.cdc.gov/campylobacter/guillain-barre.html
Yuki N, Hartung H. Guillain–Barré Syndrome. New England Journal of Medicine. 2012;366(24):2294-2304. DOI: https://doi.org/10.1056/NEJMra1114525
Palaiodimou L, Stefanou MI, Katsanos AH, Fragkou PC, Papadopoulou M, Moschovos C, et al. Prevalence, clinical characteristics and outcomes of guillain−barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis. European Journal of Neurology. 2021;28(10):3517–29. DOI: https://doi.org/10.1111/ene.14860
Ramos-Xochihua L, Bravo-Armenta E, Uc-Miam M, Gamboa-Solis E, Avendaño-Venegas R. Síndrome de Guillain Barré asociado a infección por SARS-CoV-2: Reporte de caso en México. DOI: https://doi.org/10.31157/archneurosciencesmex.v26i01.258
Uncini A, Vallat J, Jacobs B. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. Journal of Neurology, Neurosurgery & Psychiatry. 2020;91(10):1105-1110. DOI: https://doi.org/10.1136/jnnp-2020-324491
Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr;268(4):1133-1170. DOI: https://doi.org/10.1007/s00415-020-10124-x
Nelson K. Invited Commentary: Influenza Vaccine and Guillain-Barre Syndrome--Is There a Risk?. American Journal of Epidemiology.2012;175(11):1129-1132. DOI: https://doi.org/10.1093/aje/kws194
Arce Gálvez L, Ramírez Abadía L, de los Reyes Guevara C, Hernández Orozco J. Guillain-Barre syndrome after vaccination for Covid-19. The first report in Latin America. Neurology Perspectives. 2021;1(4):236-238. DOI: https://doi.org/10.1016/j.neurop.2021.09.002
Zito A, Alfonsi E, Franciotta D, Todisco M, Gastaldi M, Cotta Ramusino M et al. COVID-19 and Guillain–Barré Syndrome: A Case Report and Review of Literature. Frontiers in Neurology. 2020;11. DOI: https://doi.org/10.3389/fneur.2020.00909
Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID‐19: A systematic review and current update. Acta Neurologica Scandinavica. 2020;142(1):14-22. DOI: https://doi.org/10.1111/ane.13266
Webb S, Wallace V, Martin-Lopez D, Yogarajah M. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Reports. 2020;13(6):e236182. DOI: https://doi.org/10.1136/bcr-2020-236182
Dalakas M. Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease. Neurology - Neuroimmunology Neuroinflammation.2020;7(5):e781.DOI: https://doi.org/10.1212/NXI.0000000000000781
González Aguilar V, Carrero Castillo Y, Silva de Méndez C, Mendoza L, Batista Castro Z. Afectación Respiratoria y Sistémica producida por el Virus SARS-Cov-2. [Internet].2022[citado28Abril2022]. https://doi.org/10.31243/mdc.uta.v5i4.1424.2021
Sheikh AB, Chourasia PK, Javed N, Chourasia MK, Suriya SS, Upadhyay S, Ijaz F, Pal S, Moghimi N, Shekhar R. Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review. J Neuroimmunol. 2021 Jun 15;355:577577. DOI: https://doi.org/10.1016/j.jneuroim.2021.577577
McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020 Jun;19(6):102537 DOI: https://doi.org/10.1016/j.autrev.2020.102537
Rajabally Y, Uncini A. Outcome and its predictors in Guillain–Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 2012;83(7):711-718. DOI: https://doi.org/10.1136/jnnp-2011-301882
McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Reports. 2021;14(7). DOI: https://doi.org/10.1136/bcr-2021-244125
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Eduardo Saadi Neto, Sofia Aliss, Stephani Gonzales
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
